文献速递淋巴瘤造血干细胞移植与细胞治疗

CD27与CD70缺陷的扩展临床与免疫表型及移植结局

Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency.
PubMed 文献 · Blood · 2020-01-01

多机构全球协作收集29个家系49例CD27或CD70缺陷患者(CD27 n=33,CD70 n=16),其中24例既往未报道,共鉴定CD27突变16种、CD70突变8种。多数患者诊断时EBV阳性(90%),淋巴增殖和淋巴瘤为主要表现(70%和43%),19例在成年前行异基因造血干细胞移植,95%无病复发存活。

要点

  • CD27或CD70缺陷患者以EBV相关免疫失调为主,淋巴增殖和淋巴瘤常见(70%和43%)。
  • 43%患者出现自身炎症特征,包括葡萄膜炎、关节炎和周期性发热。
  • 19例在成年前行异基因造血干细胞移植,95%存活且无疾病复发。

核心结论

  • CD27和CD70缺陷患者具有明显的淋巴瘤易感性。
  • 异基因造血干细胞移植后的良好结局支持及时实施该治疗方式,尤其是在出现恶性转化为淋巴瘤的患者中。

研究设计与样本

  • 多机构全球协作收集29个家系49例CD27或CD70缺陷患者的临床信息(CD27 n=33;CD70 n=16),包括24例既往未报道个体。
  • 共鉴定CD27基因16种不同突变和CD70基因8种不同突变。

主要发现

  • 90%的患者诊断时EBV阳性,但仅约30%表现为传染性单核细胞增多症。
  • 淋巴增殖和淋巴瘤为主要临床表现(分别70%和43%),9例CD27缺陷患者发生HLH。
  • 21例患者(43%)出现自身炎症特征,包括葡萄膜炎、关节炎和周期性发热。
  • 免疫学分析显示记忆B细胞和T细胞生成异常,包括EBV特异性T细胞稀少和CD8+ T细胞效应功能受损。
  • 19例患者在成年前行异基因造血干细胞移植,主要因淋巴瘤,95%存活且无疾病复发。

关键数值与推荐

  • CD27缺陷患者33例,CD70缺陷患者16例。
  • 诊断时EBV阳性者占90%,表现为传染性单核细胞增多症者约30%。
  • 淋巴增殖占70%,淋巴瘤占43%,自身炎症特征占43%。
  • 9例CD27缺陷患者发生HLH。
  • 19例患者行异基因造血干细胞移植,95%存活且无疾病复发。

临床怎么用

  • 原文结论认为异基因造血干细胞移植后的良好结局支持及时实施该治疗方式,尤其在出现恶性转化为淋巴瘤的患者中。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Biallelic mutations in the genes encoding CD27 or its ligand CD70 underlie inborn errors of immunity (IEIs) characterized predominantly by Epstein-Barr virus (EBV)-associated immune dysregulation, such as chronic viremia, severe infectious mononucleosis, hemophagocytic lymphohistiocytosis (HLH), lymphoproliferation, and malignancy. A comprehensive understanding of the natural history, immune characteristics, and transplant outcomes has remained elusive. Here, in a multi-institutional global collaboration, we collected the clinical information of 49 patients from 29 families (CD27, n = 33; CD70, n = 16), including 24 previously unreported individuals and identified a total of 16 distinct mutations in CD27, and 8 in CD70, respectively. The majority of patients (90%) were EBV+ at diagnosis, but only ∼30% presented with infectious mononucleosis. Lymphoproliferation and lymphoma were the main clinical manifestations (70% and 43%, respectively), and 9 of the CD27-deficient patients developed HLH. Twenty-one patients (43%) developed autoinflammatory features including uveitis, arthritis, and periodic fever. Detailed immunological characterization revealed aberrant generation of memory B and T cells, including a paucity of EBV-specific T cells, and impaired effector function of CD8+ T cells, thereby providing mechanistic insight into cellular defects underpinning the clinical features of disrupted CD27/CD70 signaling. Nineteen patients underwent allogeneic hematopoietic stem cell transplantation (HSCT) prior to adulthood predominantly because of lymphoma, with 95% survival without disease recurrence. Our data highlight the marked predisposition to lymphoma of both CD27- and CD70-deficient patients. The excellent outcome after HSCT supports the timely implementation of this treatment modality particularly in patients presenting with malignant transformation to lymphoma.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Ghosh S, Köstel Bal S, Edwards ESJ, et al. Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency. Blood. 2020. PMID: 32603431. doi:10.1182/blood.2020006738

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。